Aldeyra Therapeutics Inc
ALDX5.080USD
+0.270+5.61%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
305.03MCap. mercado
PérdidaP/E TTM
Más Datos de Aldeyra Therapeutics Inc Compañía
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Información de la empresa
Símbolo de cotizaciónALDX
Nombre de la empresaAldeyra Therapeutics Inc
Fecha de salida a bolsaMay 02, 2014
Director ejecutivoDr. Todd C. Brady, M.D., Ph.D.
Número de empleados9
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 02
Dirección131 Hartwell Avenue
CiudadLEXINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02421
Teléfono17817614904
Sitio Webhttps://www.aldeyra.com/
Símbolo de cotizaciónALDX
Fecha de salida a bolsaMay 02, 2014
Director ejecutivoDr. Todd C. Brady, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.42M
+23.16%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
14.81K
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Independent Director
Independent Director
--
--
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Ben R. Bronstein, M.D.
Dr. Ben R. Bronstein, M.D.
Independent Director
Independent Director
--
--
Ms. Nancy B. Miller-Rich
Ms. Nancy B. Miller-Rich
Independent Director
Independent Director
--
--
Mr. William (Chip) Clark
Mr. William (Chip) Clark
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Alfieri
Mr. Michael (Mike) Alfieri
Principal Financial Officer and Principal Accounting Officer
Principal Financial Officer and Principal Accounting Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.42M
+23.16%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
14.81K
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Independent Director
Independent Director
--
--
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Knoll Capital Management, LLC
9.14%
Perceptive Advisors LLC
8.14%
The Vanguard Group, Inc.
6.21%
BlackRock Institutional Trust Company, N.A.
5.70%
Ardsley Advisory Partners LP
2.92%
Other
67.89%
Accionistas
Accionistas
Proporción
Knoll Capital Management, LLC
9.14%
Perceptive Advisors LLC
8.14%
The Vanguard Group, Inc.
6.21%
BlackRock Institutional Trust Company, N.A.
5.70%
Ardsley Advisory Partners LP
2.92%
Other
67.89%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
19.59%
Hedge Fund
16.52%
Investment Advisor/Hedge Fund
9.81%
Private Equity
8.14%
Individual Investor
3.13%
Research Firm
2.42%
Pension Fund
0.17%
Bank and Trust
0.10%
Family Office
0.08%
Other
40.04%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
293
35.88M
59.90%
-7.96M
2025Q1
315
40.31M
67.37%
-4.94M
2024Q4
306
39.84M
66.72%
-5.42M
2024Q3
295
38.52M
64.82%
-5.60M
2024Q2
290
37.23M
62.65%
-8.21M
2024Q1
294
37.04M
62.88%
-7.70M
2023Q4
296
36.84M
62.63%
-6.52M
2023Q3
298
39.89M
68.07%
-12.41M
2023Q2
305
41.03M
70.05%
-8.66M
2023Q1
311
38.11M
64.83%
-12.64M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Knoll Capital Management, LLC
5.48M
9.14%
--
--
Mar 31, 2025
Perceptive Advisors LLC
4.88M
8.14%
-4.40M
-47.44%
Apr 03, 2025
The Vanguard Group, Inc.
3.72M
6.21%
-38.77K
-1.03%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.41M
5.7%
-50.91K
-1.47%
Mar 31, 2025
Ardsley Advisory Partners LP
1.75M
2.92%
+600.00K
+52.17%
Mar 31, 2025
Brady (Todd C)
1.42M
2.38%
+267.69K
+23.16%
Apr 14, 2025
Kennedy Capital Management LLC
1.23M
2.06%
-235.10K
-16.01%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.14M
1.9%
+18.27K
+1.63%
Mar 31, 2025
State Street Global Advisors (US)
1.02M
1.71%
-11.99K
-1.16%
Mar 31, 2025
Kingdon Capital Management, L.L.C.
779.00K
1.3%
+779.00K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.8%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Vanguard US Momentum Factor ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.8%
iShares Micro-Cap ETF
Proporción0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.02%
Vanguard US Momentum Factor ETF
Proporción0.02%
Global X Russell 2000 ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
